FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280595854> ?p ?o ?g. }

• W4280595854 endingPage "786" @default.
• W4280595854 startingPage "777" @default.
• W4280595854 abstract "Abstract Delayed platelet engraftment (DPE) is associated with poor survival and increased transplantation‐related mortality after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Therefore, treatments are needed to improve platelet engraftment and prevent DPE. We performed a phase three, non‐inferior, randomized controlled study of eltrombopag or recombinant human thrombopoietin (rhTPO) to promot platelet engraftment after allo‐HSCT. Candidates for allo‐HSCT were randomly assigned to receive oral eltrombopag (50 mg daily) or subcutaneous rhTPO (15000U daily) from the first‐day post‐transplantation. The primary endpoint was the cumulative numbers of platelet engraftment (platelet recovery ≥20 × 10 9 /L, without transfusion, for seven consecutive days) on day 60 after transplantation. We performed intention‐to‐treat analyses with a non‐inferior margin of −15%. A total of 92 participants underwent randomization. 44 and 48 patients were randomized to the eltrombopag and rhTPO groups, respectively. The median duration of follow‐up was 360 days (range: 12–960 days). The cumulative incidence of platelet engraftment on day 60 after transplantation in eltrombopag group was 86.4% (38/44) compared with 85.4% (41/48) in the rhTPO group (absolute risk difference [ARD] 1%, one‐sided lower limit of 95% confidence interval [CI] −13.28%, P non‐inferirioty = 0.014). The rate of DPE in the eltrombopag group was 6.8% (3/44) compared with 12.5% (6/48) in the rhTPO group (ARD ‐5.7%, one‐sided higher limit of 95% CI 6.28%, P non‐inferirioty = 0.063). Approximately, three‐fourths of non‐hematologic adverse events were not observed in the eltrombopag group but three patients (3/48, 6%) experienecd them in the rhTPO group. In addition, platelet transfusions unite from day 0 to day 21, or from day 22 to day 60, progression‐free survival, overall survival were not significantly different between both groups. Eltrombopag was non‐inferior to rhTPO in promoting platelet engraftment post allo‐HSCT for patients with hematological malignancy. Oral eltrombopag was more convenient for patients than subcutaneous rhTPO (NCT03515096)." @default.
• W4280595854 created "2022-05-22" @default.
• W4280595854 creator A5008640532 @default.
• W4280595854 creator A5016171730 @default.
• W4280595854 creator A5019472234 @default.
• W4280595854 creator A5020720546 @default.
• W4280595854 creator A5024712687 @default.
• W4280595854 creator A5027883397 @default.
• W4280595854 creator A5061664113 @default.
• W4280595854 creator A5066767946 @default.
• W4280595854 creator A5070775744 @default.
• W4280595854 creator A5076587936 @default.
• W4280595854 date "2022-05-18" @default.
• W4280595854 modified "2023-09-26" @default.
• W4280595854 title "Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non‐inferiority, randomized controlled trial" @default.
• W4280595854 cites W1890881866 @default.
• W4280595854 cites W193514409 @default.
• W4280595854 cites W193519295 @default.
• W4280595854 cites W1969903307 @default.
• W4280595854 cites W1971846792 @default.
• W4280595854 cites W1986803999 @default.
• W4280595854 cites W1993960588 @default.
• W4280595854 cites W1999178905 @default.
• W4280595854 cites W2003000085 @default.
• W4280595854 cites W2011722739 @default.
• W4280595854 cites W2013946336 @default.
• W4280595854 cites W2022453639 @default.
• W4280595854 cites W2025122282 @default.
• W4280595854 cites W2038818733 @default.
• W4280595854 cites W2073189639 @default.
• W4280595854 cites W2076049388 @default.
• W4280595854 cites W2079110478 @default.
• W4280595854 cites W2080702239 @default.
• W4280595854 cites W2084556030 @default.
• W4280595854 cites W2084671684 @default.
• W4280595854 cites W2086647861 @default.
• W4280595854 cites W2088005749 @default.
• W4280595854 cites W2103818290 @default.
• W4280595854 cites W2106339572 @default.
• W4280595854 cites W2115135044 @default.
• W4280595854 cites W2120119492 @default.
• W4280595854 cites W2128570566 @default.
• W4280595854 cites W2133542270 @default.
• W4280595854 cites W2145139769 @default.
• W4280595854 cites W2149080680 @default.
• W4280595854 cites W2169047364 @default.
• W4280595854 cites W2202298688 @default.
• W4280595854 cites W2270431576 @default.
• W4280595854 cites W2336834983 @default.
• W4280595854 cites W2399735063 @default.
• W4280595854 cites W2411063333 @default.
• W4280595854 cites W2464419173 @default.
• W4280595854 cites W2611249007 @default.
• W4280595854 cites W2906628609 @default.
• W4280595854 cites W2911085022 @default.
• W4280595854 cites W2917676089 @default.
• W4280595854 cites W30608508 @default.
• W4280595854 cites W3128312312 @default.
• W4280595854 cites W3217268637 @default.
• W4280595854 cites W4242459101 @default.
• W4280595854 cites W4247672258 @default.
• W4280595854 cites W4280595854 @default.
• W4280595854 doi "https://doi.org/10.1002/hon.3017" @default.
• W4280595854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35554955" @default.
• W4280595854 hasPublicationYear "2022" @default.
• W4280595854 type Work @default.
• W4280595854 citedByCount "4" @default.
• W4280595854 countsByYear W42805958542022 @default.
• W4280595854 countsByYear W42805958542023 @default.
• W4280595854 crossrefType "journal-article" @default.
• W4280595854 hasAuthorship W4280595854A5008640532 @default.
• W4280595854 hasAuthorship W4280595854A5016171730 @default.
• W4280595854 hasAuthorship W4280595854A5019472234 @default.
• W4280595854 hasAuthorship W4280595854A5020720546 @default.
• W4280595854 hasAuthorship W4280595854A5024712687 @default.
• W4280595854 hasAuthorship W4280595854A5027883397 @default.
• W4280595854 hasAuthorship W4280595854A5061664113 @default.
• W4280595854 hasAuthorship W4280595854A5066767946 @default.
• W4280595854 hasAuthorship W4280595854A5070775744 @default.
• W4280595854 hasAuthorship W4280595854A5076587936 @default.
• W4280595854 hasBestOaLocation W42805958542 @default.
• W4280595854 hasConcept C126322002 @default.
• W4280595854 hasConcept C141071460 @default.
• W4280595854 hasConcept C168563851 @default.
• W4280595854 hasConcept C197934379 @default.
• W4280595854 hasConcept C203092338 @default.
• W4280595854 hasConcept C204243189 @default.
• W4280595854 hasConcept C2776689292 @default.
• W4280595854 hasConcept C2777408962 @default.
• W4280595854 hasConcept C2780588981 @default.
• W4280595854 hasConcept C2911091166 @default.
• W4280595854 hasConcept C2993327898 @default.
• W4280595854 hasConcept C71924100 @default.
• W4280595854 hasConcept C88879693 @default.
• W4280595854 hasConcept C89560881 @default.
• W4280595854 hasConcept C90924648 @default.
• W4280595854 hasConceptScore W4280595854C126322002 @default.
• W4280595854 hasConceptScore W4280595854C141071460 @default.

• next